Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: bevacizumab
DATE: 05/10/2022
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
